Altogether, these findings support that Akt-mTOR-GSK3β pathway is a key target for therapy in ischemic diseases (Matsui et al., 2001; Shiraishi et al., 2004; Sussman et al., 2011; Lin et al., 2015). Here, AKT1 is linked to ischemic disease.